USANA Health Sciences (USNA)
(Delayed Data from NYSE)
$39.50 USD
+0.10 (0.25%)
Updated Aug 6, 2024 04:00 PM ET
After-Market: $39.46 -0.04 (-0.10%) 7:58 PM ET
5-Strong Sell of 5 5
A Value C Growth B Momentum A VGM
Brokerage Reports
USANA Health Sciences, Inc. [USNA]
Reports for Purchase
Showing records 81 - 100 ( 129 total )
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Thesis Strengthened at Earnings Call; Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: BAIN D
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Should Rerate Higher; Raising Estimates, TP (+$19)
Provider: Roth Capital Partners, Inc.
Analyst: BAIN D
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
China?s Crackdown on MLM Recruiting Practice
Provider: JL Warren Capital LLC
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Dropping Coverage Due to Analyst Departure
Provider: WEDBUSH SECURITIES INC.
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Second Consecutive Quarterly Miss, but Management Maintains 2014 Guidance; Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q2 Consumer Sector Preview: PII Appears Most Likely to Beat/Raise
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q1 Miss and Lowered Guidance on Weakening U.S. and China Concerns; Maintain NEUTRAL, Lowering PT to $70
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q1 Consumer Sector Preview: HLF Most Likely to Beat/Raise, but HOG and ELY Face Near-Term Challenges
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q4 Results Above, with Forecasts, but Partially Due to Taxes; Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q4 Consumer Sector Preview: Snowmobile Manufacturers Most Likely to Benefit from Recent Weather Conditions
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q3 Results in Line with Forecasts, 2013 Guidance Slightly Below Consensus; Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Q3 Consumer Sector Preview: Polaris Appears the Most Likely to Beat Q3 Forecasts,While Callaway Golf Most Likely at Risk
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Management Outlines New Initiatives to Simplify Pricing and Broaden Compensation Program; Maintain NEUTRAL
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
Upcoming Potential Catalysts, Significant Events and Research Review Week of August 12 - 16
Provider: WEDBUSH SECURITIES INC.
Analyst: FREEDMAN C
Company: USANA Health Sciences, Inc.
Industry: Medical - Drugs
One-Time Revenue Helps Drive Q2 Upside, but Management Expects 2H Deceleration
Provider: WEDBUSH SECURITIES INC.
Analyst: DIONISIO R